Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine BiopharmaSBFMW 34 EV-to-OCF is 0.00 as of Sep. 09, 2026. GuruFocus rates SBFMW with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Sunshine Biopharma ranks better than 68.79% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sunshine Biopharma's Enterprise Value is $0.00 Mil.
Sunshine Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-5.35 Mil. Therefore, Sunshine Biopharma's EV-to-OCF for today is 0.00.
The historical rank and industry rank for Sunshine Biopharma's EV-to-OCF or its related term are showing as below:
SBFMW'
s EV-to-OCF Range Over the Past 10 Years
Min: -4.82 Med: 0.83 Max: 9.18
Current: 1.61
During the past 13 years, the highest EV-to-OCF of Sunshine Biopharma was 9.18. The lowest was -4.82. And the median was 0.83.
SBFMW's EV-to-OCF is ranked better than 68.79% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.38
vs SBFMW: 1.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunshine Biopharma's PE Ratio (TTM) for today is calculated as:
Sunshine Biopharma's share price for today is $0.0851.
Sunshine Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sunshine Biopharma EV-to-OCF Related Terms
Sunshine Biopharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's EV-to-OCF falls into.
Sunshine Biopharma's current Enterprise Value is $0.00 Mil.
Sunshine Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (SBFMW) has a EV-to-OCF of 0.00 as of Sep. 09, 2026. According to the industry distribution chart, Sunshine Biopharma ranks #314 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Sunshine Biopharma's EV-to-OCF too high?
Sunshine Biopharma's current EV-to-OCF is 0.00. Based on the distribution chart, Sunshine Biopharma ranks #314 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sunshine Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's EV-to-OCF compare to BUDZ and CVSI?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #314 out of 1006 companies for EV-to-OCF. This puts Sunshine Biopharma in the upper half of its industry. The industry median EV-to-OCF is 10.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.38, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Sunshine Biopharma (SBFMW) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sunshine Biopharma (SBFMW), the current EV-to-OCF is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFMW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFMW has been successfully added to your 
